Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173


Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.

Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E, Murch AR, Gout AM, Carter KW, Charles AK, Phillips MB, Kees UR, Beesley AH.

Oncogene. 2013 Sep 26;32(39):4664-74. doi: 10.1038/onc.2012.487. Epub 2012 Nov 5.


Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy.

Engleson J, Soller M, Panagopoulos I, Dahlén A, Dictor M, Jerkeman M.

BMC Cancer. 2006 Mar 16;6:69.


BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA.

Cancer Res. 2003 Jan 15;63(2):304-7.


BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.

French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME, Kutok JL, Toretsky JA, Tadavarthy AK, Kees UR, Fletcher JA, Aster JC.

Oncogene. 2008 Apr 3;27(15):2237-42. Epub 2007 Oct 15.


Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.

Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, Uro-Coste E, de Braud F, Pelosi G, French CA.

Cancer Discov. 2016 May;6(5):492-500. doi: 10.1158/2159-8290.CD-15-1335. Epub 2016 Mar 14.


BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).

French CA, Miyoshi I, Aster JC, Kubonishi I, Kroll TG, Dal Cin P, Vargas SO, Perez-Atayde AR, Fletcher JA.

Am J Pathol. 2001 Dec;159(6):1987-92.


NUT midline carcinoma of the parotid gland with mesenchymal differentiation.

den Bakker MA, Beverloo BH, van den Heuvel-Eibrink MM, Meeuwis CA, Tan LM, Johnson LA, French CA, van Leenders GJ.

Am J Surg Pathol. 2009 Aug;33(8):1253-8. doi: 10.1097/PAS.0b013e3181abe120.


Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.

Wang R, Liu W, Helfer CM, Bradner JE, Hornick JL, Janicki SM, French CA, You J.

Cancer Res. 2014 Jun 15;74(12):3332-43. doi: 10.1158/0008-5472.CAN-13-2658. Epub 2014 Apr 15.


New developments in the molecular pathogenesis of head and neck tumors: a review of tumor-specific fusion oncogenes in mucoepidermoid carcinoma, adenoid cystic carcinoma, and NUT midline carcinoma.

Bhaijee F, Pepper DJ, Pitman KT, Bell D.

Ann Diagn Pathol. 2011 Feb;15(1):69-77. doi: 10.1016/j.anndiagpath.2010.12.001. Review.


A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma.

Stirnweiss A, McCarthy K, Oommen J, Crook ML, Hardy K, Kees UR, Wilton SD, Anazodo A, Beesley AH.

Oncogenesis. 2015 Nov 9;4:e174. doi: 10.1038/oncsis.2015.33.


NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.

French CA, Rahman S, Walsh EM, Kühnle S, Grayson AR, Lemieux ME, Grunfeld N, Rubin BP, Antonescu CR, Zhang S, Venkatramani R, Dal Cin P, Howley PM.

Cancer Discov. 2014 Aug;4(8):928-41. doi: 10.1158/2159-8290.CD-14-0014. Epub 2014 May 29.


A rare Japanese case with a NUT midline carcinoma in the nasal cavity: a case report with immunohistochemical and genetic analyses.

Suzuki S, Kurabe N, Minato H, Ohkubo A, Ohnishi I, Tanioka F, Sugimura H.

Pathol Res Pract. 2014 Jun;210(6):383-8. doi: 10.1016/j.prp.2014.01.013. Epub 2014 Feb 22.


Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.

Yan J, Diaz J, Jiao J, Wang R, You J.

J Biol Chem. 2011 Aug 5;286(31):27663-75. doi: 10.1074/jbc.M111.246975. Epub 2011 Jun 7.


NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.

Suzuki S, Kurabe N, Ohnishi I, Yasuda K, Aoshima Y, Naito M, Tanioka F, Sugimura H.

Pathol Res Pract. 2015 May;211(5):404-8. doi: 10.1016/j.prp.2014.10.013. Epub 2014 Nov 13.


Midline carcinoma of children and young adults with NUT rearrangement.

French CA, Kutok JL, Faquin WC, Toretsky JA, Antonescu CR, Griffin CA, Nose V, Vargas SO, Moschovi M, Tzortzatou-Stathopoulou F, Miyoshi I, Perez-Atayde AR, Aster JC, Fletcher JA.

J Clin Oncol. 2004 Oct 15;22(20):4135-9.


NUT midline carcinoma: an aggressive intrathoracic neoplasm.

Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR.

J Thorac Oncol. 2013 Oct;8(10):1335-8. doi: 10.1097/JTO.0b013e3182a00f41.


Demystified molecular pathology of NUT midline carcinomas.

French CA.

J Clin Pathol. 2010 Jun;63(6):492-6. doi: 10.1136/jcp.2007.052902. Epub 2008 Jun 13. Review.


NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary.

Shehata BM, Steelman CK, Abramowsky CR, Olson TA, French CA, Saxe DF, Ricketts RR, Katzenstein HM.

Pediatr Dev Pathol. 2010 Nov-Dec;13(6):481-5. doi: 10.2350/09-10-0727-CR.1. Epub 2009 Dec 17.


Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.

Wang R, You J.

J Biol Chem. 2015 Jan 30;290(5):2744-58. doi: 10.1074/jbc.M114.600759. Epub 2014 Dec 15.


First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.

Vulsteke C, Lurquin E, Debiec-Rychter M, Gheysens O, Nuyts S, Schoenaers J, Politis C, Mebis J, Hauben E, Clement PM.

J Chemother. 2016 Jun;28(3):242-6. doi: 10.1179/1973947815Y.0000000046.


Supplemental Content

Support Center